Paratek Pharmaceuticals (PRTK) Presents New NUZYRA Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St falls as bond yields test multi-decade highs
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
October 13, 2022 4:05 PM EDTHighlights include data from non-clinical and microbiology programs and real-world patient use
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from the NUZYRA® (omadacycline) non-clinical and investigator-initiated research programs will be presented at IDWeek 2022.
The hybrid conference will be held from Oct. 19-23 at the Walter... More
